HSCT	hematopoietic stem cell transplantation
Allo-HSCT	allogeneic hematopoietic stem cell transplantation
HSC	hematopoietic stem cells
PTCy	Post-transplant cyclophosphamide
AL	acute leukemias
AML	acute myeloid leukemia
ALL	acute lymphoblastic leukemia
MPAL	mixed-phenotype leukemia
IL Infant	acute leukemia
DNA	deoxyribonucleic acid
RNA	ribonucleic acid
miRNA	microRNA
GVHD	graft-versus-host disease
aGVHD	acute graft-versus-host disease
cGVHD	chronic graft-versus-host disease
IST	immunosuppressive therapy
ATG	antithymocyte globulin
CNS	central nervous system
BFM	Berlin–Frankfurt–Münster
FAB	French–American–British classification
MRD	minimal residual disease
MaRD	matched related donor
MUD	matched unrelated donor
MMRD	mismatched related donor
NG2	neutron glial antigen-2
NGS	next-generation sequencing
TLS	tumor lysis syndrome
COG	Children’s Oncology Group
JPLSG	The Japanese Pediatric Leukemia/Lymphoma Study Group
CLABSI	central line-associated bloodstream infection
EFS	event-free survival
TBI	total body irradiation
qPCR	real-time quantitative PCR
CAR-T	chimeric antigen receptor therapy
OS	overall survival
DFS	disease-free survival
IQR	interquartile range
MAGIC	Mount Sinai Acute GVHD International Consortium CLABSI—central line-associated bloodstream infection
CMV	cytomegalovirus
BKV	BK virus
ADV	adenovirus
VOD	veno-occlusive disease
R/R	relapsed/refractory
MSCs	mesenchymal stem cells
CR	complete remission
NIH	National Institutes of Health